Koers TrovaGene Inc Nasdaq
Aandelen
US8972384080
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 390K 359K | Omzet 2025 * | 66,67K 61,35K | Marktkapitalisatie | 162 mln. 149 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -45 mln. -41,41 mln. | Nettowinst (verlies) 2025 * | -57 mln. -52,45 mln. | EV/omzet 2024 * | 416 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2.435 x |
K/w-verhouding 2024 * |
-3,71
x | K/w-verhouding 2025 * |
-3,42
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,33% |
Recentste transcriptie over TrovaGene Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 04-03-13 |
James Levine
DFI | Director of Finance/CFO | 53 | 12-07-21 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 11-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 22-04-20 |
Gary Pace
BRD | Director/Board Member | 76 | 22-04-20 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 04-03-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-0,09% | 42,12 mld. | |
+49,62% | 42,05 mld. | |
-4,96% | 29,18 mld. | |
+11,18% | 26,02 mld. | |
-21,95% | 18,9 mld. | |
+8,61% | 13,21 mld. | |
+24,73% | 12,17 mld. | |
+28,31% | 12,16 mld. | |
-6,26% | 11,42 mld. |